Advertisement

help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chung, C. T.
Right arrow Articles by Carlson, R. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chung, C. T.
Right arrow Articles by Carlson, R. W.
The Oncologist, Vol. 8, No. 6, 514–520, December 2003
© 2003 AlphaMed Press


ORIGINAL PAPER
Breast Cancer

Goals and Objectives in the Management of Metastatic Breast Cancer

Cathie T. Chunga, Robert W. Carlsonb

a Division of Oncology, Stanford University, Stanford, California, USA; b Division of Oncology, Stanford University, Palo Alto, California, USA

Correspondence: Robert W. Carlson, M.D., Division of Oncology, Stanford University, 1000 Welch Road #202, Palo Alto, California 94304, USA. Telephone: 650-725-6457; Fax: 650-725-8222; e-mail: rcarlson{at}stanford.edu

Patients with metastatic breast cancer consist of a heterogeneous group of patients whose prognoses and clinical courses can vary depending on host factors, such as comorbidity and age, and on tumor factors, such as hormone-receptor status, grade, and anatomical site of disease. Although the median survival time for patients with metastatic breast cancer is 2–4 years, subsets of patients with either indolent or limited metastatic disease may have prolonged survival times. Further, expectations of treatment, both in terms of efficacy and of toxicity, vary greatly based upon the specific treatment, patient characteristics, and tumor characteristics. Thus, the goals of treatment for patients with metastatic breast cancer are influenced by estimates of prognoses as well as a balance between physician and patient preferences regarding efficacy and toxicity considerations. Traditionally, objective measures of response and survival have been the targeted end points in clinical trial design and in physician selection of therapy for metastatic breast cancer. More recently, issues of quality of life have surfaced as important end points, especially from the perspective of the patient. The decision-making process in selecting the optimal treatment for patients with metastatic breast cancer is, therefore, a multidimensional process involving subjective as well as objective goals of treatment. Ultimately, the benefits of treatment must justify the risks and toxicities of the treatment, and the impact of treatment should be measured in relation to specified goals. Both physician and patient perspectives are important in establishing the objectives of treatment, and this process is optimally an interactive and ongoing process throughout the course of disease.

Key Words. Goals of treatment • Metastatic breast cancer




This article has been cited by other articles:


Home page
Qual Health ResHome page
E. Kenne Sarenmalm, A.-L. Thoren-Jonsson, F. Gaston-Johansson, and J. Ohlen
Making Sense of Living Under the Shadow of Death: Adjusting to a Recurrent Breast Cancer Illness
Qual Health Res, August 1, 2009; 19(8): 1116 - 1130.
[Abstract] [PDF]


Home page
Health Educ BehavHome page
C. Magai, N. S. Consedine, B. A. Adjei, D. Hershman, and A. Neugut
Psychosocial Influences on Suboptimal Adjuvant Breast Cancer Treatment Adherence Among African American Women: Implications for Education and Intervention
Health Educ Behav, December 1, 2008; 35(6): 835 - 854.
[Abstract] [PDF]


Home page
Ann OncolHome page
X. Pivot, P. Koralewski, J. L. Hidalgo, A. Chan, A. Goncalves, G. Schwartsmann, S. Assadourian, and J. P. Lotz
A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients
Ann. Onc., September 1, 2008; 19(9): 1547 - 1552.
[Abstract] [Full Text] [PDF]


Home page
Am J Health Syst PharmHome page
L. B. Michaud
Treatment-experienced breast cancer
Am. J. Health Syst. Pharm., May 15, 2008; 65(10_Supplement_3): S4 - S9.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
N. P. S. Crawford, J. Alsarraj, L. Lukes, R. C. Walker, J. S. Officewala, H. H. Yang, M. P. Lee, K. Ozato, and K. W. Hunter
Bromodomain 4 activation predicts breast cancer survival
PNAS, April 29, 2008; 105(17): 6380 - 6385.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
B. L. Andersen, K. M. Carpenter, H.-C. Yang, and C. L. Shapiro
Sexual Well-Being Among Partnered Women With Breast Cancer Recurrence
J. Clin. Oncol., July 20, 2007; 25(21): 3151 - 3157.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
C. A. Huff, W. Matsui, B. D. Smith, and R. J. Jones
The paradox of response and survival in cancer therapeutics
Blood, January 15, 2006; 107(2): 431 - 434.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
T. Friess, W. Scheuer, and M. Hasmann
Combination Treatment with Erlotinib and Pertuzumab against Human Tumor Xenografts Is Superior to Monotherapy
Clin. Cancer Res., July 15, 2005; 11(14): 5300 - 5309.
[Abstract] [Full Text] [PDF]




HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2003 by AlphaMed Press.
Advertisement